Lynch syndrome in the hands of the urologist

Česká verzia

Authors: Tomáš Pitra ¹; Kristýna Pivovarčíková ²; Hana Sedláčková ¹; Ondřej Hes ²; Milan Hora ¹; Ondřej Daum ²
Authors place of work: Urologická klinika LF UK a FN Plzeň ¹; Šiklův ústav patologie LF UK a FN Plzeň ²
Published in the journal: Ces Urol 2017; 21(4): 272-279
Category: Review article

Summary

Major statement:
Review dealing with Lynch syndrome, its presentation, diagnosis, treatment and surveillance in the urinary tract. Lynch syndrome (LS) is an inherited autosomal dominant cancer syndrome. It presents in young/ middle aged patients and it predisposes individuals to wide spectrum of malignancies in different organs (the most frequent are tumors of colon and endomemetrium). LS is typically associated with upper urinary tract urothelial carcinoma (UUTUC), which is considered to be the third most frequent tumor in LS. Recently, a large number of papers have been published calling for the determination of optimal strategies in screening, detection, surveillance and management of patients with LS. Despite this clear association between UUTUC and LS, there are no well-defined strategies in common use, which can be routinely applied in clinical practice. At present, the most effective and safe surveillance protocols are unknown.

Key words:
Lynch syndrome, hereditary disease, urothelial carcinoma, upper urinary tract.

Zdroje

1. Barrow P, Khan M, Lalloo F, Evans DG, Hill J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg. 2013; 100(13): 1719–1731.

2. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993; 75(5): 1027–1038.

3. Nyström‑Lahti M, Wu Y, Moisio AL, et al. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary non‑polyposis colorectal cancer. Hum Mol Genet. 1996; 5(6): 763–769.

4. Wijnen J, van der Klift H, Vasen H, et al. MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet. 1998; 20(4): 326–328.

5. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004; 96(4): 261–268.

6. Lynch HT, Ens JA, Lynch JF. The Lynch syndrome II and urological malignancies. J Urol. 1990; 143(1): 24–28.

7. Sijmons RH, Kiemeney LA, Witjes JA, Vasen HF. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. The Journal of urology. 1998; 160(2): 466–470.

8. Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol. 2008; 26(5): 451–464.

9. Joost P, Therkildsen C, Dominguez‑Valentin M, Jönsson M, Nilbert M. Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 2015; 86(6): 1212–1217.

10. Rouprêt M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol. 2008; 54(6): 1226–1236.

11. Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer. 2012; 48(4): 456–464.

12. Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res. 1994; 14(4 B): 1635–1639.

13. Crockett DG, Wagner DG, Holmäng S, Johansson SL, Lynch HT. Upper urinary tract carcinoma in Lynch syndrome cases. J Urol. 2011; 185(5): 1627–1630.

14. Sidransky D, Frost P, Vohttps://www.centrum.cz/?redirected=1503167932n Eschenbach A, et al. Clonal origin of bladder cancer. N Engl J Med. 1992; 326(11): 737–740.

15. van der Post RS, Kiemeney LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of medical genetics. 2010; 47(7): 464–470.

16. Skeldon SC, Semotiuk K, Aronson M, et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 2013; 63(2): 379–385.

17. Maul JS, Warner NR, Kuwada SK, Burt RW, Cannon‑Albright

LA. Extracolonic cancers associated with hereditary nonpolyposis colorectal cancer in the Utah Population Database. Am J Gastroenterol. 2006; 101(7): 1591–1596.

18. Burger M, Denzinger S, Hammerschmied CG, et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl). 2006; 84(10): 833–841.

19. Velasco A, Riquelme E, Schultz M, et al. Mismatch repair gene expression and genetic instability in testicular germ cell tumor. Cancer Biol Ther. 2004; 3(10): 977–982.

20. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non‑Polyposis Colorectal Cancer (ICG‑HNPCC). Dis Colon Rectum. 1991; 34(5): 424–425.

21. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116(6): 1453–1456.

22. Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst. 2009; 101(5): 331–340.

23. Piñol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005; 293(16): 1986–1994.

24. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first‑line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel maybe as predictive as a 4-antibody panel. Am J Surg Pathol. 2009; 33(11): 1639–1645.

25. Funkhouser WK, Lubin IM, Monzon FA, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair‑defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn. 2012; 14(2): 91–103.

26. Halvarsson B, Lindblom A, Rambech E, Lagerstedt K, Nilbert M. Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer? Virchows Arch. 2004; 444(2): 135–141.

27. Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2017; doi: 10.1016/j.eururo.2017. 07. 036. [Epub ahead of print].

28. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006; 296(12): 1507–1517.

29. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999; 87(3): 118–128.

30. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol. 1985; 29(5): 810–816.

31. Raab SS, Lenel JC, Cohen MB. Low grade transitional cell carcinoma of the bladder. Cytologic diagnosis by key features as identified by logistic regression analysis. Cancer 1994; 74(5): 1621–1626.

32. Myrhøj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer 2008; 7(4): 303–307.

33. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009; 10(4): 400–408.

34. Acher P, Kiela G, Thomas K, O‘Brien T. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non‑polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int. 2010; 106(3): 300–302.

35. Pradere B, Lotan Y, Roupret M. Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance. Curr Opin Urol. 2017; 27(1): 48–55.

36. Audenet F, Colin P, Yates DR, et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi‑institutional database analysis: proposal of patient‑specific risk identification tool. BJU Int. 2012; 110 (11 Pt B): E583–9.

37. Rouprêt M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol. 2011; 59(4): 584–594.

38. Daum O, Beneš Z, Ladislav H, et al. Lynchův syndrom v rukách patologa. Česko‑Slovenská patologie 2014; 50(1): 18–24.